ciprofloxacin has been researched along with Arthritis, Post-Infectious in 19 studies
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.
ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The value of antibiotics in the treatment of reactive arthritis (ReA) is still controversial." | 2.71 | Effect of a three month course of ciprofloxacin on the late prognosis of reactive arthritis. ( Hakola, M; Korpela, M; Luukkainen, R; Möttönen, T; Sanila, M; Toivanen, A; Uksila, J; Yli-Kerttula, T; Yli-Kerttula, U, 2003) |
| "Ciprofloxacin was not effective in Yersinia- or Salmonella-induced arthritis but seemed to be better than placebo in Chlamydia-induced arthritis." | 2.69 | No benefit of long-term ciprofloxacin treatment in patients with reactive arthritis and undifferentiated oligoarthritis: a three-month, multicenter, double-blind, randomized, placebo-controlled study. ( Alten, R; Braun, J; Eggens, U; Fendler, C; Granfors, K; Gripenberg-Lerche, C; Groh, A; Hiepe, F; Keitel, W; Laitko, S; Sieper, J; Sörensen, H; Uksila, J, 1999) |
| "Treatment of reactive arthritis (ReA) with antibiotics has so far remained controversial." | 2.69 | Effect of a three month course of ciprofloxacin on the outcome of reactive arthritis. ( Hakola, M; Korpela, M; Luukkainen, R; Möttönen, T; Parviainen, J; Sanila, M; Toivanen, A; Uksila, J; Vainionpää, R; Yli-Kerttula, T; Yli-Kerttula, U, 2000) |
| "Patients with yersinia triggered reactive arthritis were double blind randomly allocated to receive treatment with ciprofloxacin 500 mg twice daily orally or placebo during three months." | 2.69 | Ciprofloxacin v placebo for treatment of Yersinia enterocolitica triggered reactive arthritis. ( Bruyn, GA; Hoogkamp-Korstanje, JA; Moesker, H, 2000) |
| "Sulfasalazine, which has an effect in the acute exacerbations of ankylosing spondylitis, is probably also effective in chronic reactive arthritis." | 2.38 | Are antibiotics of any use in reactive arthritis? ( Leirisalo-Repo, M, 1993) |
| "Diagnosis of postenteritic reactive arthritis (ReA) is a challenge and might have a broad range of differential diagnoses." | 1.51 | Reactive arthritis secondary to ( Bibbò, S; Colombo, E; Dore, MP; Erre, GL, 2019) |
| "Postvenereal reactive arthritis is an inflammatory form of arthritis that commonly develops after urogenital infection, predominantly in human leucocyte antigen-B27-positive men in the third decade of life." | 1.40 | Detection of bacteria and analyses of Chlamydia trachomatis viability in patients with postvenereal reactive arthritis. ( Bojović, J; Cikota-Aleksić, B; Magić, Z; Miličić, B; Pavlica, L; Strelić, N, 2014) |
| "We conclude that experimental Yersinia reactive arthritis can be cured by antibiotics introduced at an early phase of arthritic development." | 1.30 | Experimental Yersinia-triggered reactive arthritis: effect of a 3-week course of ciprofloxacin. ( Toivanen, A; Toivanen, P; Zhang, Y, 1997) |
| "The basic mechanisms underlying reactive arthritis and specifically the joint injury that follows intra-articular Chlamydia trachomatis infection have not been defined." | 1.30 | Synoviocyte-packaged Chlamydia trachomatis induces a chronic aseptic arthritis. ( Chiu, B; Inman, RD, 1998) |
| " Adverse events, premature discontinuation of therapy, and deaths occurred at a similar frequency in both treatment arms." | 1.30 | Safety of long-term therapy with ciprofloxacin: data analysis of controlled clinical trials and review. ( Haverstock, D; Reinhart, H; Segev, S; Yaniv, I, 1999) |
| " If a dosage of 20 mg/kg/day was used, development of acute arthritis was prevented, but some of the animals had positive fecal cultures at the end of experiment." | 1.29 | Antibiotic prophylaxis and treatment of reactive arthritis. Lessons from an animal model. ( Gripenberg-Lerche, C; Söderström, KO; Toivanen, A; Toivanen, P; Zhang, Y, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 9 (47.37) | 18.2507 |
| 2000's | 8 (42.11) | 29.6817 |
| 2010's | 2 (10.53) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Erre, GL | 1 |
| Colombo, E | 1 |
| Bibbò, S | 1 |
| Dore, MP | 1 |
| Strelić, N | 1 |
| Bojović, J | 1 |
| Pavlica, L | 1 |
| Cikota-Aleksić, B | 1 |
| Miličić, B | 1 |
| Magić, Z | 1 |
| Sieper, J | 2 |
| Braun, J | 2 |
| Appelboom, T | 1 |
| Emery, P | 1 |
| Tant, L | 1 |
| Dumarey, N | 1 |
| Schoutens, A | 1 |
| Yli-Kerttula, T | 2 |
| Luukkainen, R | 2 |
| Yli-Kerttula, U | 2 |
| Möttönen, T | 2 |
| Hakola, M | 2 |
| Korpela, M | 2 |
| Sanila, M | 2 |
| Uksila, J | 3 |
| Toivanen, A | 6 |
| Taylor-Robinson, D | 1 |
| Gilroy, CB | 1 |
| Horowitz, S | 1 |
| Horowitz, J | 1 |
| Leirisalo-Repo, M | 1 |
| Zhang, Y | 2 |
| Gripenberg-Lerche, C | 2 |
| Söderström, KO | 1 |
| Toivanen, P | 3 |
| Uystepruyst, P | 1 |
| Tellier, E | 1 |
| Dardenne, B | 1 |
| Darimont, M | 1 |
| Inman, RD | 2 |
| Chiu, B | 1 |
| Segev, S | 1 |
| Yaniv, I | 1 |
| Haverstock, D | 1 |
| Reinhart, H | 1 |
| Fendler, C | 1 |
| Laitko, S | 1 |
| Sörensen, H | 1 |
| Hiepe, F | 1 |
| Alten, R | 1 |
| Keitel, W | 1 |
| Groh, A | 1 |
| Eggens, U | 1 |
| Granfors, K | 1 |
| Wakefield, D | 1 |
| McCluskey, P | 1 |
| Verma, M | 1 |
| Aziz, K | 1 |
| Gatus, B | 1 |
| Carr, G | 1 |
| Parviainen, J | 1 |
| Vainionpää, R | 1 |
| Hoogkamp-Korstanje, JA | 1 |
| Moesker, H | 1 |
| Bruyn, GA | 1 |
| Stone, M | 1 |
5 reviews available for ciprofloxacin and Arthritis, Post-Infectious
| Article | Year |
|---|---|
[Diagnosis and antibiotic treatment of reactive arthritis].
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Bacterial; Arthritis, Reactive; A | 2002 |
Are antibiotics of any use in reactive arthritis?
Topics: Anti-Bacterial Agents; Arthritis, Reactive; Chlamydia Infections; Ciprofloxacin; Humans; Sulfasalazi | 1993 |
Managing reactive arthritis.
Topics: Animals; Arthritis, Reactive; Bacterial Infections; Ciprofloxacin; Disease Models, Animal; Humans; Y | 2000 |
Reactive arthritis.
Topics: Animals; Arthritis, Reactive; Chlamydia Infections; Chlamydia trachomatis; Ciprofloxacin; DNA, Bacte | 2000 |
Recent developments in the therapy of spondyloarthropathies.
Topics: Alleles; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Monoclonal; Antirheumati | 2000 |
5 trials available for ciprofloxacin and Arthritis, Post-Infectious
| Article | Year |
|---|---|
Effect of a three month course of ciprofloxacin on the late prognosis of reactive arthritis.
Topics: Acute Disease; Adult; Aged; Anti-Infective Agents; Arthritis, Reactive; Chronic Disease; Ciprofloxac | 2003 |
No benefit of long-term ciprofloxacin treatment in patients with reactive arthritis and undifferentiated oligoarthritis: a three-month, multicenter, double-blind, randomized, placebo-controlled study.
Topics: Adult; Aged; Anti-Infective Agents; Arthritis, Reactive; Chlamydia Infections; Chlamydia trachomatis | 1999 |
Ciprofloxacin treatment does not influence course or relapse rate of reactive arthritis and anterior uveitis.
Topics: Anti-Infective Agents; Arthritis, Reactive; Ciprofloxacin; Double-Blind Method; Female; HLA-B27 Anti | 1999 |
Effect of a three month course of ciprofloxacin on the outcome of reactive arthritis.
Topics: Adult; Anti-Infective Agents; Arthritis, Reactive; Ciprofloxacin; Double-Blind Method; Female; Human | 2000 |
Ciprofloxacin v placebo for treatment of Yersinia enterocolitica triggered reactive arthritis.
Topics: Adolescent; Adult; Aged; Animals; Anti-Infective Agents; Arthritis, Reactive; Blood Sedimentation; C | 2000 |
9 other studies available for ciprofloxacin and Arthritis, Post-Infectious
| Article | Year |
|---|---|
Reactive arthritis secondary to
Topics: Anti-Bacterial Agents; Arthritis, Reactive; Ciprofloxacin; Diagnosis, Differential; Drug Administrat | 2019 |
Detection of bacteria and analyses of Chlamydia trachomatis viability in patients with postvenereal reactive arthritis.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Arthritis, Reactive; Chlamydia Infections; Chlamydia | 2014 |
Evaluation of technetium-99m-ciprofloxacin (Infecton) for detecting sites of inflammation in arthritis.
Topics: Adult; Arthritis, Reactive; Arthritis, Rheumatoid; Chondrocalcinosis; Ciprofloxacin; Gout; Humans; O | 2003 |
Mycoplasma genitalium in the joints of two patients with arthritis.
Topics: Adult; Arthritis; Arthritis, Reactive; Arthritis, Rheumatoid; Ciprofloxacin; Humans; Knee Joint; Lup | 1994 |
Antibiotic prophylaxis and treatment of reactive arthritis. Lessons from an animal model.
Topics: Animals; Anti-Infective Agents; Antibiotic Prophylaxis; Arthritis, Reactive; Body Weight; Ciprofloxa | 1996 |
Experimental Yersinia-triggered reactive arthritis: effect of a 3-week course of ciprofloxacin.
Topics: Animals; Anti-Infective Agents; Antibodies, Bacterial; Arthritis, Reactive; Ciprofloxacin; Dose-Resp | 1997 |
[Reiter syndrome: apropos of a case].
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Arthri | 1998 |
Synoviocyte-packaged Chlamydia trachomatis induces a chronic aseptic arthritis.
Topics: Animals; Arthritis, Reactive; Bacterial Outer Membrane Proteins; Blotting, Western; Chlamydia Infect | 1998 |
Safety of long-term therapy with ciprofloxacin: data analysis of controlled clinical trials and review.
Topics: Arthritis, Reactive; Ciprofloxacin; Consumer Product Safety; Humans; Inflammatory Bowel Diseases; My | 1999 |